rs121434292 — SLC39A4 Arg95Cys

SLC39A4 Arg95Cys — The Gateway for Zinc

Your small intestine contains a protein called ZIP4, encoded by SLC39A4, that acts as the primary gateway for absorbing dietary zinc. ZIP4 sits on the apical (luminal) surface of enterocytes in the duodenum and jejunum, where it actively transports zinc ions from food into the intestinal wall — the first step in getting zinc from your plate into your bloodstream. Without a functioning ZIP4, dietary zinc passes through the gut essentially unabsorbed, no matter how much you eat.

The Arg95Cys variant (rs121434292) is a single-letter change at position 283 of the SLC39A4 coding sequence (c.283C>T), replacing arginine with cysteine at protein position 95. This missense substitution disrupts the ZIP4 protein structure and causes acrodermatitis enteropathica¹¹ acrodermatitis enteropathica
AE: a rare inherited zinc malabsorption disorder first described in 1942. It is distinct from dietary zinc deficiency — it is a genetic inability to absorb zinc from food regardless of intake, an autosomal recessive disorder first linked to SLC39A4 in a landmark 2002 study²² a landmark 2002 study
Wang K et al. A novel member of a zinc transporter family is defective in acrodermatitis enteropathica. Am J Hum Genet, 2002.

The Mechanism

ZIP4 is not a simple channel — it is a regulated transporter that dynamically shuttles between the enterocyte membrane and intracellular compartments depending on zinc availability. When dietary zinc is plentiful, ZIP4 is endocytosed and held inside the cell; when zinc is scarce, ZIP4 moves to the apical membrane to maximize absorption. This feedback loop keeps systemic zinc levels stable across a wide range of dietary intakes.

The Arg95 residue lies within the large extracellular domain of ZIP4, which is critical for correct protein folding and membrane trafficking. Functional studies of related AE missense mutations by Wang et al. 2004³³ Wang et al. 2004
Wang F et al. Acrodermatitis enteropathica mutations affect transport activity, localization and zinc-responsive trafficking of the mouse ZIP4 zinc transporter. Hum Mol Genet, 2004 demonstrated that all tested AE-associated missense variants either abolish zinc transport activity outright or impair zinc-responsive endocytosis. Arg95Cys-type substitutions in the extracellular domain are expected to disrupt protein folding and prevent correct trafficking to the cell surface — a class of defect that effectively silences the transporter.

The Evidence

Arg95Cys was first reported by Nakano et al. 2003⁴⁴ Nakano et al. 2003
Nakano A et al. Novel SLC39A4 mutations in acrodermatitis enteropathica. J Invest Dermatol, 2003 in Japanese twins presenting with the classical AE triad of periorificial dermatitis, diarrhea, and alopecia. The twins carried Arg95Cys in compound heterozygosity with a 53-bp insertion creating a premature stop codon — a typical presentation for AE, where patients are rarely true homozygotes but instead carry two different loss-of-function alleles. The mutation was absent from 100 control chromosomes screened in the same study, supporting pathogenicity.

The variant is recorded in ClinVar as Pathogenic/Likely pathogenic (VCV000003722, 2-star review, multiple submitters, no conflicts, last evaluated January 2025). It is exceptionally rare in population databases: gnomAD exomes record only 9 heterozygous carriers among 685,748 individuals screened (allele frequency ~6.6 × 10⁻⁶), with no homozygotes identified — consistent with a highly penetrant recessive disorder causing early-onset illness in the rare individuals who inherit two loss-of-function alleles.

AE itself occurs at approximately 1 in 500,000 newborns globally, though the true incidence may be higher due to misdiagnosis as nutritional zinc deficiency or other skin conditions. Without genetic confirmation and zinc supplementation, the disorder can progress to severe immune dysfunction, growth failure, neurological complications, and historically even death. With lifelong zinc supplementation, the prognosis is excellent — clinical response typically begins within days and is essentially complete.

Practical Actions

For heterozygous carriers (AG genotype): no treatment is needed. Heterozygous carriers have one functional copy of SLC39A4 and one defective copy. The single working copy provides sufficient ZIP4 activity to maintain normal zinc absorption and serum zinc levels. Carriers are clinically unaffected. The primary significance of carrier status is reproductive risk: if both parents carry a pathogenic SLC39A4 variant, each pregnancy has a 25% chance of inheriting two defective copies and developing AE.

For homozygous or compound heterozygous individuals (AA or biallelic variants): the cornerstone of treatment is lifelong oral zinc supplementation starting at 3 mg/kg/day of elemental zinc, with most children ultimately maintained at 1-3 mg/kg/day. Zinc sulfate is the most widely used formulation; zinc gluconate and zinc acetate are alternatives for those who experience gastrointestinal irritation from sulfate. Because zinc and copper share the same absorption pathway (metallothionein induction), chronic high-dose zinc supplementation can cause copper deficiency — serum copper and zinc should both be monitored every 3-6 months, with dose adjusted to the lowest level maintaining normal serum zinc (70-120 µg/dL).

Interactions

Acrodermatitis enteropathica is caused by compound heterozygosity for two different pathogenic SLC39A4 alleles in the great majority of cases — true Arg95Cys homozygotes are rarely reported. Any individual identified as an Arg95Cys carrier who develops AE symptoms should have both SLC39A4 alleles fully sequenced to identify the second pathogenic variant, which may be a different missense, nonsense, frameshift, splice-site, or structural variant in the gene.

There are no well-documented interactions between rs121434292 and variants in other zinc transporter genes (SLC30A1-10, SLC39A1-14) that meaningfully alter clinical management for carriers. The clinical ZIP4 deficiency state in homozygotes is profound enough that other transporter variants do not compensate.